Kevin Klucher

4.7k total citations
37 papers, 2.7k citations indexed

About

Kevin Klucher is a scholar working on Epidemiology, Molecular Biology and Oncology. According to data from OpenAlex, Kevin Klucher has authored 37 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Epidemiology, 13 papers in Molecular Biology and 13 papers in Oncology. Recurrent topics in Kevin Klucher's work include Cytomegalovirus and herpesvirus research (6 papers), interferon and immune responses (5 papers) and Liver Disease Diagnosis and Treatment (5 papers). Kevin Klucher is often cited by papers focused on Cytomegalovirus and herpesvirus research (6 papers), interferon and immune responses (5 papers) and Liver Disease Diagnosis and Treatment (5 papers). Kevin Klucher collaborates with scholars based in United States, Germany and Denmark. Kevin Klucher's co-authors include Leonore Reiser, Helen Chow, Robert L. Fischer, Deborah H. Spector, George Q. Daley, Peter Staeheli, Søren R. Paludan, Markus Mordstein, Georg Kochs and Laure Dumoutier and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and Blood.

In The Last Decade

Kevin Klucher

37 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kevin Klucher United States 20 1.1k 934 895 558 465 37 2.7k
Zhenming Xu United States 24 1.2k 1.1× 1.0k 1.1× 970 1.1× 280 0.5× 86 0.2× 53 2.9k
R Risser United States 27 731 0.7× 1.4k 1.5× 311 0.3× 572 1.0× 111 0.2× 57 2.9k
Xianfang Wu United States 20 672 0.6× 972 1.0× 551 0.6× 125 0.2× 55 0.1× 37 2.2k
Philippe Mangeot France 20 415 0.4× 1.3k 1.4× 579 0.6× 171 0.3× 81 0.2× 52 2.1k
Brad R. Rosenberg United States 20 742 0.7× 1.4k 1.5× 333 0.4× 250 0.4× 54 0.1× 36 2.5k
Chen Zhao China 23 1.2k 1.1× 1.2k 1.3× 534 0.6× 576 1.0× 177 0.4× 64 2.7k
Michael Niepmann Germany 29 337 0.3× 1.7k 1.8× 359 0.4× 46 0.1× 128 0.3× 44 2.7k
Linda F. van Dyk United States 27 782 0.7× 1.1k 1.2× 1.1k 1.2× 944 1.7× 106 0.2× 46 2.8k
Nicole A. de Weerd Australia 18 1.2k 1.1× 457 0.5× 261 0.3× 721 1.3× 40 0.1× 31 2.1k
Naoki Oyaizu Japan 33 2.0k 1.8× 881 0.9× 649 0.7× 365 0.7× 19 0.0× 106 3.3k

Countries citing papers authored by Kevin Klucher

Since Specialization
Citations

This map shows the geographic impact of Kevin Klucher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Klucher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Klucher more than expected).

Fields of papers citing papers by Kevin Klucher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Klucher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Klucher. The network helps show where Kevin Klucher may publish in the future.

Co-authorship network of co-authors of Kevin Klucher

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Klucher. A scholar is included among the top collaborators of Kevin Klucher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Klucher. Kevin Klucher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kirschberg, Thorsten, Christopher T. Jones, Ying‐zi Xu, et al.. (2020). Selective thyroid hormone receptor β agonists with oxadiazolone acid isosteres. Bioorganic & Medicinal Chemistry Letters. 30(21). 127465–127465. 5 indexed citations
3.
Piasecki, Julia, Kenneth Brasel, Robert Rosler, Kevin Klucher, & Scott Peterson. (2017). Abstract 578: Discovery and characterization of novel antagonistic antibodies that bind with high affinity to human, cynomolgus, and murine TIGIT, an immune checkpoint receptor. Cancer Research. 77(13_Supplement). 578–578. 2 indexed citations
4.
Andersen, Henrik, Jeremy A. Freeman, Sean E. Doyle, et al.. (2013). Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic. Journal of Clinical and Translational Hepatology. 1(2). 116–24. 8 indexed citations
5.
Hong, David S., Daniel W. Bowles, Gerald S. Falchook, et al.. (2012). A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(15). 4173–4182. 134 indexed citations
6.
Byrnes-Blake, Kelly, Susan Pederson, Kevin Klucher, et al.. (2012). Pharmacokinetics and Pharmacodynamics of Pegylated Interferon Lambda-1 in Cynomolgus Monkeys. Journal of Interferon & Cytokine Research. 32(5). 198–206. 7 indexed citations
7.
Koltsida, Ourania, Michael Hausding, Athanasios Stavropoulos, et al.. (2011). IL‐28A (IFN‐λ2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Molecular Medicine. 3(6). 348–361. 172 indexed citations
8.
9.
Miller, Dennis M., et al.. (2009). Interferon Lambda as a Potential New Therapeutic for Hepatitis C. Annals of the New York Academy of Sciences. 1182(1). 80–87. 53 indexed citations
10.
Ank, Nina, Marie B. Iversen, Christina Bartholdy, et al.. (2008). An Important Role for Type III Interferon (IFN-λ/IL-28) in TLR-Induced Antiviral Activity. The Journal of Immunology. 180(4). 2474–2485. 358 indexed citations
11.
Mordstein, Markus, Georg Kochs, Laure Dumoutier, et al.. (2008). Interferon-λ Contributes to Innate Immunity of Mice against Influenza A Virus but Not against Hepatotropic Viruses. PLoS Pathogens. 4(9). e1000151–e1000151. 269 indexed citations
12.
Mordstein, Markus, Georg Kochs, Laure Dumoutier, et al.. (2008). 267 Interferon-λ contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. Cytokine. 43(3). 307–307. 4 indexed citations
13.
Cunningham, Charles, et al.. (2006). Inhibition of Interferon Signaling by the Kaposi's Sarcoma-Associated Herpesvirus Full-Length Viral Interferon Regulatory Factor 2 Protein. Journal of Virology. 80(6). 3092–3097. 83 indexed citations
14.
Doyle, Sean E., Katherine Henderson, Robert Rosler, et al.. (2006). Interleukin‐29 uses a type 1 interferon‐like program to promote antiviral responses in human hepatocytes†. Hepatology. 44(4). 896–906. 295 indexed citations
15.
Peters, David G., Kevin Klucher, Rita C. R. Perlingeiro, et al.. (2001). Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice. Oncogene. 20(21). 2636–2646. 35 indexed citations
16.
Salgia, Ravi, Elizabeth J. Quackenbush, Jeffrey Lin, et al.. (1999). The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha.. Blood. 94(12). 4233–46. 71 indexed citations
17.
Klucher, Kevin, et al.. (1998). Secondary Mutation Maintains the Transformed State in BaF3 Cells With Inducible BCR/ABL Expression. Blood. 91(10). 3927–3934. 88 indexed citations
18.
Klucher, Kevin. (1997). A novel method to isolate cells with conditional gene expression using fluorescence activated cell sorting. Nucleic Acids Research. 25(23). 4858–4860. 6 indexed citations
19.
Klucher, Kevin, Marvin Sommer, James T. Kadonaga, & Deborah H. Spector. (1993). In Vivo and in Vitro Analysis of Transcriptional Activation Mediated by the Human Cytomegalovirus Major Immediate-Early Proteins. Molecular and Cellular Biology. 13(2). 1238–1250. 63 indexed citations
20.
Spector, Deborah H., Kevin Klucher, D K Rabert, & Dowain A. Wright. (1990). Human Cytomegalovirus Early Gene Expression. Current topics in microbiology and immunology. 154. 21–45. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhenming Xu Breakdown of academic impact, for papers by R Risser Breakdown of academic impact, for papers by Xianfang Wu Breakdown of academic impact, for papers by Philippe Mangeot Breakdown of academic impact, for papers by Brad R. Rosenberg Breakdown of academic impact, for papers by Chen Zhao Breakdown of academic impact, for papers by Michael Niepmann Breakdown of academic impact, for papers by Linda F. van Dyk Breakdown of academic impact, for papers by Nicole A. de Weerd Breakdown of academic impact, for papers by Naoki Oyaizu
Rankless by CCL
2026